Table 1. Examples of in vivo assay descriptions and annotation.

ChEMBL_ID	Assay description	Assay classification (Level 3)	Reference source or common term∗	Key∗∗
CHEMBL772714	Adjuvant arthritic rat activity determined with respect to spirogermanium at a dose of 30 mg/kg	Adjuvant Arthritis in Rats	Hock_2016	1
CHEMBL777832	Blood pressure lowering activity in renal hypertensive rats after intravenous administration; no drop in blood pressure or a statistically insignificant drop in blood pressure was observed (in vivo)	Renal Hypertension	Hock_2016	1
CHEMBL683996	Compound was evaluated in vivo for cysLT1 receptor induced airway obstruction in guinea pig (OA) at 2.0 hour after oral administration.	General Airway Models	phenotype	2
CHEMBL716118	In vivo antimalarial activity in mice (Mus musculus) against chloroquine-resistant Plasmodium yoelii species. NS after subcutaneous administration	General Antimalarial Activity	phenotype	2
CHEMBL732290	Analgesic activity in tail flick test, oral administration	Radiant Heat Method; General Analgesic Nociceptic and Allodynic Activity	Hock_2016; phenotype	3
CHEMBL723844	Compound was administered subcutaneously and was evaluated for opioid agonist activity by antinociceptive tail-flick (TF) assay in mice; I denotes Inactive at 30 mg/kg	Radiant Heat Method; General Analgesic Nociceptic and Allodynic Activity	Hock_2016; phenotype	3
CHEMBL2328414	Antioxidant activity against CCl4-induced oxidative hepatic injury Wistar albino rat model assessed as effect on liver cytosolic catalase activity per mg protein at 100 mg/kg, ip for 7 consecutive days prior to CCL4 challenge measured 24 h post CCl4 challenge (Rvb = 218.25 +/− 11.43 U/mg protein)	Carbon tetrachloride CCl4 Induced Liver Fibrosis in Rats; General Models of Drug Induced Liver Injury	Vogel_2008; phenotype	3
CHEMBL703119	In vivo antitumor activity against L1210 leukemia in 18 mice measured as T/C value; T/C = 18/9	General Leukemia; L1210 Experimental Leukemia; Neoplasms	Phenotype; Hock_2016; phenotype	3
CHEMBL785102	In vivo binding specificity the compound in rat striatum at 60 min of intravenous injection.	—	—	4
CHEMBL732935	Compound was evaluated for the time from injection to peak inhibition of the twitch response at 0.4 mg/kg dose	—	—	4

^∗Hock_2016 is reference¹⁸, Vogel_2008 is reference¹⁷, ‘phenotype’ denotes that a common disease or phenotypic term can be identified within the assay description and annotated as such for e.g. ‘anti-Alzheimers’, ‘analgesia’, ‘inflammation’, ‘hepatotoxicity’).

^∗∗Key to final column 1: A reference animal model can be identified from the assay description and annotated by a MeSH term. 2: A disease or phenotypic endpoint with pharmacological or toxicological relevance can be identified from the assay description and annotated by a MeSH term, but there is no direct match to a specific reference animal model. 3: Both a reference animal model AND a disease or phenotypic endpoint with pharmacological or toxicological relevance can be identified from the assay description. 4: No specific reference animal model or a disease or phenotypic endpoint with pharmacological or toxicological relevance can be identified from the assay description.